# Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

> **NCT05630976** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 70 (actual)

## Conditions studied

- Invasive Fungal Disease

## Interventions

- **DRUG:** Isavuconazole

## Key facts

- **NCT ID:** NCT05630976
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-07
- **Primary completion:** 2025-04-11
- **Final completion:** 2025-04-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630976, "Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05630976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*